Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.

Pandey, Kamal; Katuwal, Nar Bahadur; Park, Nahee; Hur, Jin; Cho, Young Bin; Kim, Seung Ki; Lee, Seung Ah; Kim, Isaac; Lee, Seung-Ryeol; Moon, Yong Wha

Pandey, Kamal; Katuwal, Nar Bahadur; Park, Nahee; Hur, Jin; Cho, Young Bin; Kim, Seung Ki; Lee, Seung Ah; Kim, Isaac; Lee, Seung-Ryeol; Moon, Yong Wha.

Afiliação

Pandey K; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Katuwal NB; Department of Biomedical Science, The Graduate School, CHA University, Seongnam 13620, Korea.
Park N; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Hur J; Department of Biomedical Science, The Graduate School, CHA University, Seongnam 13620, Korea.
Cho YB; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Kim SK; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Lee SA; Department of Biomedical Science, The Graduate School, CHA University, Seongnam 13620, Korea.
Kim I; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Lee SR; Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam 13620, Korea.
Moon YW; Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam 13620, Korea.